Literature DB >> 9893041

Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions.

P Sreenivasan1, R S Misra, D Wilfred, I Nath.   

Abstract

Some leprosy patients suffer from clinical episodes associated with tissue damage which are designated as Type 1 (reversal reaction) when localized to the lesions and Type 2 (erythema nodosum leprosum, ENL) when accompanied by systemic involvement. We had reported earlier that stable, non-reaction lepromatous leprosy subjects show T helper 2 (Th2)- and Th0- but not Th1-like responses in the peripheral blood. To further understand the development of Th-like responses during disease, 32 lepromatous patients undergoing reactions were studied using cytokine-specific reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) in peripheral blood and some skin biopsies. Of interest was the evidence of a Th1-like response with presence of interferon-gamma (IFN-gamma) and absence of interleukin-4 (IL-4) mRNA in the peripheral blood mononuclear cells (PBMC) of 85 and 64% of Type 1 and 2 reaction patients, respectively, and in all reaction sites. Whereas a Th0- was seen in some, a Th2-like response was absent. IL-12p40 mRNA was seen in 21/25 ENL and all Type 1 reaction subjects irrespective of the Th phenotype. IL-12p40 and IFN-gamma were detectable in unstimulated PBMC suggesting an in vivo priming during reactions. IL-10 was mainly associated with adherent cells and showed a differential expression in the two reactions. It was present in the PBMC of ENL but not in reversal reaction patients. Moreover, it was not detectable in the skin lesions of either type of reactions. A Th1-like cytokine profile was associated with immunopathology and persisted up to 6-7 months after the onset of reactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9893041      PMCID: PMC1364348          DOI: 10.1046/j.1365-2567.1998.00634.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  Cytokine patterns of immunologically mediated tissue damage.

Authors:  M Yamamura; X H Wang; J D Ohmen; K Uyemura; T H Rea; B R Bloom; R L Modlin
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

Review 2.  Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo.

Authors:  R L Coffman; K Varkila; P Scott; R Chatelain
Journal:  Immunol Rev       Date:  1991-10       Impact factor: 12.988

3.  Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum.

Authors:  S Laal; L K Bhutani; I Nath
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

4.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones.

Authors:  P Salgame; J S Abrams; C Clayberger; H Goldstein; J Convit; R L Modlin; B R Bloom
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

5.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

6.  Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy.

Authors:  R B Narayanan; S Laal; A K Sharma; L K Bhutani; I Nath
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

7.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions.

Authors:  M Yamamura; K Uyemura; R J Deans; K Weinberg; T H Rea; B R Bloom; R L Modlin
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

8.  In situ and in vitro characterization of the cellular immune response in erythema nodosum leprosum.

Authors:  R L Modlin; V Mehra; R Jordan; B R Bloom; T H Rea
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

9.  Critical residues of the Mycobacterium leprae LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions.

Authors:  S Singh; P J Jenner; N P Narayan; G Ramu; M J Colston; H K Prasad; I Nath
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients.

Authors:  E P Sampaio; A L Moreira; E N Sarno; A M Malta; G Kaplan
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  23 in total

1.  Lsr2 peptides of Mycobacterium leprae show hierarchical responses in lymphoproliferative assays, with selective recognition by patients with anergic lepromatous leprosy.

Authors:  Mehervani Chaduvula; A Murtaza; Namita Misra; N P Shankar Narayan; V Ramesh; H K Prasad; Rajni Rani; R K Chinnadurai; Indira Nath
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Authors:  N Bahia El Idrissi; S Hakobyan; V Ramaglia; A Geluk; B Paul Morgan; P Kumar Das; F Baas
Journal:  Clin Exp Immunol       Date:  2016-03-31       Impact factor: 4.330

Review 3.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

4.  Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls.

Authors:  M T Collins; G Lisby; C Moser; D Chicks; S Christensen; M Reichelderfer; N Høiby; B A Harms; O O Thomsen; U Skibsted; V Binder
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

5.  Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment.

Authors:  D Little; S Khanolkar-Young; A Coulthart; S Suneetha; D N Lockwood
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 6.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

7.  High-resolution sonography: a new technique to detect nerve damage in leprosy.

Authors:  Suman Jain; Leo H Visser; T L N Praveen; P Narasimha Rao; Thummalakunta Surekha; Ramesh Ellanti; Thummalakunta L N Abhishek; Indira Nath
Journal:  PLoS Negl Trop Dis       Date:  2009-08-11

8.  Lsr2 of Mycobacterium leprae and its synthetic peptides elicit restitution of T cell responses in erythema nodosum leprosum and reversal reactions in patients with lepromatous leprosy.

Authors:  Chaman Saini; H K Prasad; Rajni Rani; A Murtaza; Namita Misra; N P Shanker Narayan; Indira Nath
Journal:  Clin Vaccine Immunol       Date:  2013-02-27

9.  Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.

Authors:  A Iyer; M Hatta; R Usman; S Luiten; L Oskam; W Faber; A Geluk; P Das
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

10.  Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker.

Authors:  Fátima Regina Vilani-Moreno; Vânia Nieto Brito-de-Souza; Sônia Maria Usó Ruiz Silva; Adriana Sierra Assêncio Almeida Barbosa; Beatriz Gomes Carreira Sartori; Ana Paula Campanelli; Jaison Antonio Barreto; Marcos da Cunha Lopes Virmond
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Mar-Apr       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.